Close Menu

NEW YORK (GenomeWeb) – Exosome Diagnostics said today that it has agreed to collaborate with Intezyne to design and validate an exosomal RNA assay for use in Intezyne's Phase 1/2 clinical trials of IT-139, a novel Cancer Resistance Pathway (CRP) inhibitor intended for the treatment of pancreatic, gastric, and other cancers in combination with existing anti-cancer therapies.

The assay will use Exosome Diagnostics' Exolution isolation kit and will be designed to stratify patients and monitor them longitudinally.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.

Dec
01
Sponsored by
Roche

Management of viral infections is critical to prevent severe morbidities and consequences in immune-suppressed transplant patients.

Dec
03
Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.